Deerfield Management ABSI Position
Exited5-Fund ConvergenceDeerfield Management exited their position in Absci Corp (ABSI) in Q4 2024, after holding the stock for 4 quarters.
The position was first reported in Q1 2024 and has been tracked across 4 quarterly 13F filings.
ABSI is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ABS-201 IV Single Dose in 839 days (Jul 31, 2028), making the timing of Deerfield's position particularly relevant.
Short interest stands at 29.1% of float with 13.6 days to cover, indicating significant bearish positioning against the stock.
About Absci Corp
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Full company profile →Short Interest
29.1%
13.6 days to cover
Deerfield Management ABSI Position History
Frequently Asked Questions
Does Deerfield Management own ABSI?
No. Deerfield Management exited their position in Absci Corp (ABSI) in Q4 2024. They previously held the stock for 4 quarters.
How many hedge funds own ABSI?
5 specialist biotech hedge funds currently hold ABSI, including Redmile Group, Casdin Capital, Baker Bros. Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ABSI?
Deerfield Management's position in ABSI was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ABSI position increasing or decreasing?
Deerfield Management completely exited their ABSI position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABSICompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →